Summary: Intranasal administration has become a promising alternative route of delivery to mitigate challenges like gastrointestinal degradation or high first pass loss in gut wall and/or liver after oral delivery. It may also offer advantages such as increased compliance for patients with swallowing problems, quick onset of action, local treatment, and direct access to the brain. But before initiating formulation development, it is desirable to assess whether the API is suitable for intranasal delivery. The aim of this study was to verify if the GastroPlus® PBPK software can be used to predict intranasal absorption by comparing predictions with human intranasal pharmacokinetic data from the literature.
PBPK Modeling as a Strategic Tool to Predict Intranasal Drug Absorption